• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[应用NONMEM法评估肾移植患者中环孢素A的群体药代动力学]

[Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM].

作者信息

Rui J Z, Zhuo H T, Jiang G H, Chen G

机构信息

Department of Clinical Pharmacology, General Hospital of Nanjing Armed Forces.

出版信息

Yao Xue Xue Bao. 1995;30(4):241-7.

PMID:7660791
Abstract

NONMEM program was applied for estimating population pharmacokinetic parameters of cyclosporin A (CsA). The influence of body weight, age, sex and drug administration history on clearance were investigated. There were 281 CsA concentrations in whole blood from 60 clinical renal transplantation patients. Samples were analysed by HPLC and FPIA (TDx, Abbott, monoclonal antibody). One compartment open model with first-order absorption and elimination was used to analyse the data. Population mean values of CL(L.h-1), Vd(L), and Ka(h-1) were 59.8, 227, and 1.28 respectively. The interindividual variations of CL, Vd, and Ka were 30.27%, 29.01%, and 75.10% respectively. The residual error was 31.19%. The adjustment value of weight to clearance was 0.03 times with additional model. CL increased 4.31 in male patients, and decreased 12.7 when patients were treated with CsA for a long time.

摘要

使用NONMEM程序估算环孢素A(CsA)的群体药代动力学参数。研究了体重、年龄、性别和用药史对清除率的影响。收集了60例临床肾移植患者全血中的281个CsA浓度样本。采用高效液相色谱法(HPLC)和荧光偏振免疫分析法(FPIA,TDx,雅培公司,单克隆抗体)对样本进行分析。采用一级吸收和消除的一室开放模型对数据进行分析。清除率(CL,L·h-1)、分布容积(Vd,L)和吸收速率常数(Ka,h-1)的群体均值分别为59.8、227和1.28。CL、Vd和Ka的个体间变异分别为30.27%、29.01%和75.10%。残差误差为31.19%。在附加模型中,体重对清除率的校正值为0.03倍。男性患者的CL增加4.31,长期使用CsA治疗的患者CL降低12.7。

相似文献

1
[Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM].[应用NONMEM法评估肾移植患者中环孢素A的群体药代动力学]
Yao Xue Xue Bao. 1995;30(4):241-7.
2
Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.儿童肾移植患者中环孢素的群体药代动力学及贝叶斯估计
Ther Drug Monit. 2007 Feb;29(1):96-102. doi: 10.1097/FTD.0b013e3180310f9d.
3
[Pharmacokinetics of cyclosporin A in renal transplant patients after infusion].[环孢素A在肾移植患者输注后的药代动力学]
Zhongguo Yao Li Xue Bao. 1991 Nov;12(6):528-30.
4
Population pharmacokinetics of cyclosporine in clinical renal transplant patients.环孢素在临床肾移植患者中的群体药代动力学。
Drug Metab Dispos. 2005 Sep;33(9):1268-75. doi: 10.1124/dmd.105.004358. Epub 2005 Jun 2.
5
Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.类风湿关节炎患者同时使用甲氨蝶呤时依那西普的药代动力学未改变。
J Clin Pharmacol. 2004 Nov;44(11):1235-43. doi: 10.1177/0091270004268049.
6
Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.环孢素(新山地明)在初次肾移植患者中的时间依赖性药代动力学。
J Clin Pharm Ther. 2005 Dec;30(6):549-57. doi: 10.1111/j.1365-2710.2005.00683.x.
7
Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome.环孢素在肾病综合征患者中的群体药代动力学研究。
J Clin Pharmacol. 2009 Jul;49(7):782-8. doi: 10.1177/0091270009337132. Epub 2009 May 15.
8
Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.环孢素A治疗犬特应性皮炎的药代动力学及疗效
J Vet Pharmacol Ther. 2004 Aug;27(4):231-8. doi: 10.1111/j.1365-2885.2004.00587.x.
9
Population pharmacokinetics of albendazole in patients with neurocysticercosis.阿苯达唑在神经囊尾蚴病患者中的群体药代动力学。
Int J Clin Pharmacol Ther. 2009 Nov;47(11):679-85.
10
A study of the interaction between omeprazole and cyclosporine in renal transplant patients.肾移植患者中奥美拉唑与环孢素相互作用的研究。
Br J Clin Pharmacol. 1993 Feb;35(2):156-60.

引用本文的文献

1
Population pharmacokinetics of cyclosporine in transplant recipients.移植受者环孢素的群体药代动力学。
AAPS J. 2013 Oct;15(4):901-12. doi: 10.1208/s12248-013-9500-8. Epub 2013 Jun 18.